Multiple myeloma · 13 regimens
Cost vs Efficacy · 7 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carfilzomib and Panobinostat Variant #01 Partial | — | R 231 582 | 28d | — | — | ~3 | ~R 359 189 indirect | — |
Carfilzomib and Dexamethasone (Kd) Variant #01 | — | R 175 476 | 28d | ~13.2 mo | ~45.7 mo | ~10 | ~R 1 071 413 PFS proxy · indirect | 8 |
Thalidomide and Dexamethasone (TD) Variant #06 | — | R 64 543 | 30d | ~18.6 mo | ~63.2 mo | ~18 | ~R 678 160 PFS proxy · indirect | 3 |
Ixazomib and Dexamethasone Variant #01 | — | R 33 351 | 28d | — | — | ~2 | ~R 66 702 indirect | — |
Pomalidomide and Dexamethasone (Pd) Variant #01 | — | R 29 040 | 28d | ~6.5 mo | ~17.4 mo | ~2 | ~R 58 079 PFS proxy · indirect | 13 |
Bortezomib and Pegylated liposomal doxorubicin Variant #01 | — | R 18 762 | 21d | — | — | ~9 | ~R 168 858 indirect | — |
Bortezomib and Dexamethasone (Vd) Variant #01 | — | R 7 456 | 28d | ~9.4 mo | ~38.7 mo | ~8 | ~R 59 651 PFS proxy · indirect | 10 |
Bortezomib and Vorinostat Variant #01 Partial | — | R 6 762 | 21d | ~7.6 mo | — | ~2 | ~R 13 524 PFS proxy · indirect | 1 |
Lenalidomide and Dexamethasone (Rd) Variant #02 | — | R 4 309 | 28d | ~21.0 mo | ~55.4 mo | ~40 | ~R 132 764 PFS proxy · indirect | 26 |
Cyclophosphamide and Dexamethasone Variant #01 | — | R 1 411 | 28d | — | ~10.0 mo | ~2 | ~R 2 822 PFS proxy · indirect | 1 |
Selinexor and Dexamethasone (Sd) Variant #01 Partial | — | R 694 | 28d | — | — | ~2 | ~R 1 389 indirect | — |
Melphalan flufenamide and Dexamethasone Variant #01 Partial | — | R 347 | 28d | ~6.8 mo | — | ~2 | ~R 694 PFS proxy · indirect | 1 |
Cyclophosphamide and Prednisone Variant #02 | — | R 17 | — | — | ~10.0 mo | ~1 | ~R 17 PFS proxy · indirect | 1 |
13 of 13 regimens shown